Core Insights - The Titan SGS™ Stapler is associated with significantly lower rates of postoperative gastroesophageal reflux disease (GERD) and shorter hospital stays compared to traditional multi-fire staplers in robotic-assisted laparoscopic sleeve gastrectomy (LSG) procedures [1][3][4] - A retrospective analysis of 257 patients showed that at one year post-procedure, 7.1% of patients using the Titan SGS™ Stapler reported GERD, compared to 26.4% in the multi-fire cohort [3][4] - The study highlights the importance of consistent surgical techniques in achieving better patient outcomes, particularly in reducing GERD incidence [2][3] Company Overview - Teleflex Incorporated is a leading global provider of medical technologies, focusing on improving health and quality of life through innovative solutions [5][6] - The Titan SGS™ Stapler is the first single-fire surgical stapler specifically designed for sleeve gastrectomy pouch creation, featuring a 23cm staple line for improved surgical outcomes [3][4] - The company aims to enhance the adoption of bariatric surgery by addressing common postoperative complications such as GERD [3][5]

Core Insights - Teleflex Incorporated (TFX) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.91, a decrease of 9.3% year-over-year, but exceeded the Zacks Consensus Estimate by 1% [1] - The company's net revenues fell 5% year-over-year to $700.7 million, surpassing the Zacks Consensus Estimate by 0.2% [2] Revenue Breakdown - Revenues in the Americas segment were $475.7 million, down 3.7% year-over-year [3] - EMEA segment revenues decreased 5.3% year-over-year to $151.2 million [3] - Asia segment revenues fell 12.8% to $73.8 million [4] Product Revenue Performance - Vascular Access segment revenues increased by 1.9% year-over-year to $182.4 million [5] - Interventional business revenues rose 3.2% year-over-year to $137.5 million [5] - Anesthesia segment revenues decreased 8.6% year-over-year to $86.6 million [6] - Surgical segment revenues increased by 2% year-over-year to $105.8 million [6] - Interventional Urology segment revenues fell 10.7% year-over-year to $71 million [6] - OEM revenues decreased by 26.8% year-over-year to $63.9 million [7] - Other product segment revenues increased by 4.5% year-over-year to $53.5 million [7] Margin and Profitability - Gross profit was $389.4 million, down 6.4% year-over-year, with a gross margin of 55.6%, a contraction of 82 basis points [8] - Adjusted operating profit was $130.3 million, down 4.2% year-over-year, but the adjusted operating margin expanded by 17 basis points to 18.6% [9] Liquidity and Cash Flow - Teleflex ended Q1 2025 with cash and cash equivalents of $284.1 million, down from $290.2 million at the end of Q4 2024 [10] - Net cash flow from operating activities was $73.3 million, compared to $112.8 million in the prior year [11] Updated Guidance - The company now expects GAAP revenue growth for 2025 to be in the range of 1.28-2.28%, revised from a prior guidance of a decline of 0.4% to growth of 0.7% [12] - Adjusted EPS guidance for 2025 is now projected to be between $13.20 and $13.60, down from the previous range of $13.95 to $14.35 [12] Strategic Developments - Teleflex has entered into an agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG, which will enhance its product portfolio and market presence [15] - The acquisition includes a range of vascular intervention devices, positioning the company for continued growth [15]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Teleflex Incorporated due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Teleflex's stock price, which fell by 21.6% on February 27, 2025, following the announcement of a company split and a €760 million deal with Biotronik [3]. - Shareholders who purchased Teleflex securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Teleflex Incorporated due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Teleflex securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Teleflex [2]. Group 2: Stock Performance and Company News - On February 27, 2025, Teleflex's stock fell by 21.6% following the announcement of a plan to split the company and acquire cardiovascular device assets from Biotronik [3]. - The announcement was made during market hours and was reported by Fierce Biotech [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

Core Viewpoint - The Schall Law Firm is investigating Teleflex Incorporated for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Teleflex issued false or misleading statements or failed to disclose critical information to investors [2]. - A significant event triggering the investigation was an article published by Fierce Biotech on February 27, 2025, which reported Teleflex's plan to split its business into two independent companies and acquire a new portfolio of cardiovascular device assets from Biotronik [2]. - Following the announcement of the business split and acquisition, Teleflex's shares experienced a sharp decline of 21.6% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is reaching out to shareholders who may have suffered losses and encourages them to discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Insights - Teleflex reported revenue of $700.67 million for the quarter ended March 2025, a decrease of 5% year-over-year, with EPS at $2.91 compared to $3.21 in the same quarter last year, indicating a slight revenue surprise of +0.22% over the Zacks Consensus Estimate and an EPS surprise of +1.04% [1] Financial Performance - Revenue breakdown shows significant geographic performance: - Americas: $475.70 million, exceeding the estimated $418.41 million, reflecting a +17.1% year-over-year change - Asia: $73.80 million, below the estimated $77.13 million - EMEA: $151.20 million, slightly below the estimated $154.16 million [4] - Net revenues in key segments: - Interventional: $137.50 million, close to the estimated $137.85 million, with a +2.1% year-over-year change - Interventional Urology: $71 million, above the estimated $69.11 million, but down -10.9% year-over-year - OEM: $63.90 million, below the estimated $70.27 million, down -27.1% year-over-year - Vascular Access: $182.40 million, slightly above the estimated $178.12 million, with a +0.6% year-over-year change - Anesthesia: $86.60 million, below the estimated $92.40 million, down -10.2% year-over-year - Other: $53.50 million, above the estimated $49.30 million, with a +2.1% year-over-year change - Surgical: $105.80 million, above the estimated $102.08 million, with a +0.3% year-over-year change [4] Market Performance - Teleflex shares have returned -3.1% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, indicating underperformance relative to the broader market [3]

Financial Data and Key Metrics Changes - For Q1 2025, Teleflex reported revenues of $700.7 million, a decrease of 5% year over year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [5][27] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [5][25] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [23] - Adjusted operating margin was 24.7%, a decline of 190 basis points year over year [23] Business Line Data and Key Metrics Changes - **Americas**: Revenues were $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift office site [6][7] - **EMEA**: Revenues decreased by 2.8% year over year to $151.2 million, with strong performance in Surgical and Vascular Access offset by anesthesia [8] - **Asia**: Revenues were $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement in China [9] - **Vascular Access**: Revenue increased by 1.9% year over year to $182.4 million, driven by growth in PICCs [9] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by growth in complex catheters [10] - **Anesthesia**: Revenue decreased by 8.6% year over year to $86.6 million, impacted by tough comps in military orders [11] - **Surgical**: Revenue increased by 2% year over year to $105.8 million, with solid underlying trends [12] - **OEM**: Revenue decreased by 26.8% year over year to $63.9 million, primarily due to a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [5] - The Asia market faced challenges due to volume-based procurement, but sequential quarterly revenue improvement is expected through the remainder of 2025 [9] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [18][19] - The acquisition of BioTronix's Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the headwinds faced in Q1, including OEM business pressures and UroLift declines, are expected to be transitory [35] - The company anticipates sequential improvement in revenue from China and expects to navigate tariff impacts through various mitigation strategies [30][31] Other Important Information - The company has initiated an accelerated share repurchase program, completing it in April 2025, which returned capital to shareholders [26] - The updated financial guidance for 2025 includes adjusted constant currency revenue growth expectations of 1% to 2% and adjusted EPS in the range of $13.2 to $13.6 [27][31] Q&A Session Summary Question: Has there been any incremental demand on the OEM side of the business? - Management noted a pickup in demand within the OEM business as the quarter progressed, indicating base demand rather than supply chain issues [42][43] Question: Can you provide more details on the $55 million tariff impact? - The $55 million figure reflects current tariffs and does not include any mitigation strategies. Management is exploring various strategies to mitigate tariff impacts [47][49] Question: What is the interest level in NewCo? - There is significant interest in NewCo, with a healthy mix of both strategic and private equity interest, and the company is open to exploring all options to maximize shareholder value [60][76] Question: How will tariffs impact RemainCo and SpinCo? - Management indicated that tariffs will impact both entities, but specifics will be discussed closer to the separation date [82] Question: What are the early views on cost and revenue synergies from BioTronix? - The focus will be on leveraging the BioTronix channel in Europe and the Teleflex channel in the Americas to drive revenue growth [84]

Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.04%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.86 per share when it actually produced earnings of $3.89, delivering a surprise of 0.78%.Over the last four quarters, the co ...

Financial Data and Key Metrics Changes - Teleflex reported Q1 2025 revenues of $700.7 million, a 5% decrease year over year on a GAAP basis, and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [6][24] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [6][24] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [22] - Adjusted operating margin was 24.7%, a 190 basis point decline year over year [22] Business Line Data and Key Metrics Changes - **Americas**: Revenues were $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift service [7] - **EMEA**: Revenues decreased 2.8% year over year to $151.2 million, with strong performance in Surgical and Vascular Access offset by anesthesia [8] - **Asia**: Revenues were $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement impacts [8] - **Vascular Access**: Revenue increased 1.9% year over year to $182.4 million, driven by growth in PICCs [9] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by strong demand for intra-aortic balloon pumps [10] - **Anesthesia**: Revenue decreased 8.6% year over year to $86.6 million, with growth in endotracheal tubes offset by declines in military orders [11] - **Surgical**: Revenue increased 2% year over year to $105.8 million, with solid underlying trends [11] - **Interventional Urology**: Revenue decreased 10.7% year over year to $71 million, with strong growth in BarriGel but pressure on UroLift [12] - **OEM**: Revenue decreased 26.8% year over year to $63.9 million, impacted by a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [6] - The China business is expected to see sequential quarterly revenue improvement through the remainder of 2025 [9] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [17][18] - The acquisition of BioTronix Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [19][20] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter evolved largely as expected, with specific headwinds anticipated to be transitory [33] - The company expects 2025 adjusted constant currency revenue growth of 1% to 2%, with an updated guidance range for reported revenue growth [26] - Tariffs are expected to impact 2025 results, with an estimated $55 million headwind, primarily associated with China and Mexico [28][29] Other Important Information - The company is actively exploring strategies to mitigate tariff exposure, including optimizing the supply chain and increasing the mix of USMCA compliant products [29][30] - The company has implemented thoughtful spending controls to offset tariff impacts [53] Q&A Session Summary Question: Has there been any incremental demand on the OEM side due to supply chain issues? - Management noted a pickup in demand within the OEM business, indicating base demand rather than supply chain issues [41] Question: Can you provide more details on the $55 million tariff impact and mitigation strategies? - Management explained that the $55 million is based on current tariffs and does not include mitigation strategies, which are being explored [46][52] Question: What is the interest level in NewCo, and is there a preference for a sale versus a spin? - Management indicated significant interest in NewCo, with a parallel process for both spin and sale being pursued [59][64] Question: How does the tariff impact split between RemainCo and SpinCo? - Management stated that the impact of tariffs will affect both entities, but specifics will be discussed closer to the separation date [81] Question: What are the early views on cost and revenue synergies from the BioTronix acquisition? - Management highlighted the opportunity to leverage BioTronix's channel in Europe and Teleflex's channel in the Americas for revenue growth [84]

Financial Data and Key Metrics Changes - Teleflex reported revenues of $700.7 million for Q1 2025, a decrease of 5% year over year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [5][6] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [5][26] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [23] - Adjusted operating margin was 24.7%, a decline of 190 basis points year over year [23] Business Line Data and Key Metrics Changes - **Americas Revenues**: $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift office site [6] - **EMEA Revenues**: $151.2 million, down 2.8% year over year, with strong performance in Surgical and Vascular Access offset by anesthesia [7] - **Asia Revenues**: $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement in China [7][8] - **Vascular Access**: Revenue increased 1.9% year over year to $182.4 million, driven by growth in PICCs [8] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by growth in complex catheters [9] - **Anesthesia**: Revenue decreased 8.6% year over year to $86.6 million, with growth in endotracheal tubes offset by tough comps [11] - **Surgical**: Revenue increased 2% year over year to $105.8 million, with solid underlying trends [12] - **OEM Revenue**: Decreased 26.8% year over year to $63.9 million, impacted by a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [5] - The China business is expected to see sequential quarterly revenue improvement through the remainder of 2025 [8] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [18][19] - The acquisition of BioTronix Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [20][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter evolved largely as expected, with specific headwinds anticipated to be transitory [35] - The company expects to return to growth and create shareholder value despite current challenges, including tariffs and customer contract losses [35][36] - Adjusted EPS guidance for 2025 has been revised to a range of $13.2 to $13.6, reflecting headwinds from tariffs and other factors [31] Other Important Information - The company is actively exploring strategies to mitigate tariff exposure, including optimizing the supply chain and increasing the mix of USMCA compliant products [31][32] - The total addressable global market for treating coronary vessel perforation is estimated to exceed $80 million, highlighting growth opportunities in the vascular intervention space [21] Q&A Session Summary Question: Has there been any incremental demand on the OEM side of the business? - Management noted a pickup in demand within the OEM business, with order rates improving as the quarter progressed [43][44] Question: Can you provide more details on the $55 million tariff impact? - The $55 million figure reflects current tariffs and does not include mitigation strategies. Management is exploring various strategies to mitigate the impact [48][52] Question: Is there significant interest in NewCo? - There is a healthy mix of interest from both strategic and private equity firms, with a focus on maximizing shareholder value [73][87] Question: How is the interventional urology business performing? - The interventional urology business is performing in line with expectations, with strong growth in the Palette product [100][101]